At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 1,805 enrolled
Drug / intervention
erlotinib [Tarceva]drug
Likely dose
erlotinib [Tarceva] 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label Study of the Effect of Tarceva Monotherapy on Treatment Response in Patients With Advanced Non-small Cell Lung Cancer for Whom Tarceva Monotherapy is Considered the Best Option
In Brief
A Phase 2 clinical trial evaluating erlotinib [Tarceva] for Non-Small Cell Lung Cancer. Completed, enrolled 1,805 participants across 94 sites.
Detailed Summary
This study will evaluate the efficacy and safety of oral Tarceva in patients with advanced NSCLC for whom Tarceva monotherapy is considered the best therapeutic option. The anticipated time on study treatment is 3-12 months.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesSpain
Collaborators--
Timeline
Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2004
Primary CompletionOct 2012
First PostedNov 2013
TodayJul 2026
First PostedNov 27, 2013
Enrollment StartApr 1, 2004
Primary CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 8.5 yearsPosted 12.6 years ago
Interventions
erlotinib [Tarceva]drug
150 mg/day until progressive disease or unacceptable toxicity